Anthropometric, clinical and biochemical characteristics of patients with TD2M and CKD with stable (or increased) and with decreased GFR at one year follow-up.
Continuous variables are presented as mean (S.D.) or median (interquartile range, IQR).
aP values of Mann-Whitney U or one-way ANOVA test for differences of variables among patients with stable or decreased eGFR at one year follow-up.
* Statistical significance at the 0.05 level (two-tailed).
BMI, body mass index; HbA1c, glycosylated hemoglobin A1c; RAAS blockade, use of medicines affecting renin–angiotensin system; Crea T0, serum creatinine levels at timepoint 0 (baseline); Crea T1, serum creatinine levels at timepoint 1 (12 months); eGFR T0, estimated GFR assessed by the CKD-EPI formula at timepoint 0 (baseline); eGFR T1, estimated GFR assessed by the CKD-EPI formula at timepoint 1 (12 months); PU T0, Proteinuria assessed by protein to creatinine ratio at timepoint 0 (baseline); PU T1, Proteinuria assessed by protein to creatinine ratio at timepoint 1 (12 months); ΔGFR T0-T1, Algebric difference between eGFR at timepoint 1 and eGFR at timepoint 0; ΔPU T0-T1, Algebric difference between Proteinuria at timepoint 1 (12 months) and Proteinuria at timepoint 0 (baseline); ESRD, progression to end stage renal disease; Total-CAF, serum levels of C-terminal agrin fragment; Decreased GFR, patients with loss of eGFR ≥ 1 ml/min/1.73m2 during the 12 month follow-up.
Anthropometric, clinical and biochemical characteristics of patients with TD2M and CKD with stable (or increased) and with decreased GFR at one year follow-up.
